Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters

European Journal of Pharmacology

Volumn 740, Issue , 2014, Pages 135-143

  Briand, Franc¸ois ^a   Thieblemont, Quentin ^a   Muzotte, Elodie ^a   Burr, Noémie ^a   Urbain, Isabelle ^a   Sulpice, Thierry ^a   Johns, Douglas G ^b  

^a Prologue Biotech   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cholesteryl ester transfer protein inhibition; Hamster; High density lipoprotein; Reverse cholesterol transport

Indexed keywords

ANACETRAPIB; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; HYPOCHOLESTEROLEMIC AGENT; OXAZOLIDINONE DERIVATIVE; THIOL DERIVATIVE; TRIACYLGLYCEROL;

ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; DYSLIPIDEMIA; FECES; HAMSTER; MACROPHAGE; MALE; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CRICETINAE; DYSLIPIDEMIAS; FECES; MACROPHAGES; MALE; OXAZOLIDINONES; SULFHYDRYL COMPOUNDS; TRIGLYCERIDES;

EID: 84906066645     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.06.022     Document Type: Article

References (23)

1. B.J. Arsenault, and J.P. Després HDL cholesterol is not HDL - don't judge the book by its cover Nat. Rev. Cardiol. 9 2012 557 558
2. 2+precipitation procedures for determination of high density lipoprotein cholesterol Clin. Biochem. 17 1984 166 169 (Pubitemid 14004742)
3. Cholesterol Treatment Trialists'(CTT) Collaborators C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, and R. Simes Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
4. P.J. Barter, and K.A. Rye Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk J. Lipid Res. 53 2012 1755 1766
5. F. Briand, S.U. Naik, I. Fuki, J.S. Millar, C. Macphee, M. Walker, J. Billheimer, G. Rothblat, and D.J. Rader Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol Clin. Transl. Sci 2 2009 127 133
6. F. Briand The use of dyslipidemic hamsters to evaluate drug-induced alterations in reverse cholesterol transport Curr. Opin. Investig. Drugs 11 2010 289 297
7. F. Briand, M. Tréguier, A. André, D. Grillot, M. Issandou, K. Ouguerram, and T. Sulpice Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model J. Lipid Res. 51 2010 763 770
8. F. Briand, Q. Thiéblemont, E. Muzotte, and T. Sulpice High-fat and fructose intake induces insulin resistance, dyslipidemia, and liver steatosis and alters in vivo macrophage-to-feces reverse cholesterol transport in hamsters J. Nutr. 142 2012 704 709
9. F. Briand, Q. Thieblemont, E. Muzotte, and T. Sulpice Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters Arterioscler. Thromb. Vasc. Biol. 33 2013 13 23
10. C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, A.M. Gotto, M. Stepanavage, S.X. Liu, P. Gibbons, T.B. Ashraf, J. Zafarino, Y. Mitchel, and P. Barter Safety of anacetrapib in patients with or at high risk for coronary heart disease N. Engl. J. Med. 363 2010 2406 2415
11. J. Castro-Perez, F. Briand, K. Gagen, S.P. Wang, Y. Chen, D.G. McLaren, V. Shah, R.J. Vreeken, T. Hankemeier, T. Sulpice, T.P. Roddy, B.K. Hubbard, and D.G. Johns Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters J. Lipid Res. 52 2011 1965 1973
12. H.M. Dansky, D. Bloomfield, P. Gibbons, S. Liu, C.M. Sisk, D. Tribble, J.M. McKenney, T.W. Littlejohn 3rd, and Y. Mitchel Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia Am. Heart J. 162 2011 708 716
13. A. Dillard, N.R. Matthan, and A.H. Lichtenstein Use of hamster as a model to study diet-induced atherosclerosis Nutr. Metab. (Lond.) 7 2010 89 101
14. G.S. Getz, and C.A. Reardon Animal models of atherosclerosis Arterioscler. Thromb. Vasc. Biol. 32 2012 1104 1115
15. D.E. Gutstein, R. Krishna, D. Johns, H.K. Surks, H.M. Dansky, S. Shah, Y.B. Mitchel, J. Arena, and J.A. Wagner Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction Clin. Pharmacol. Ther. 91 2012 109 122
16. N.E. Miller, D.S. Thelle, O.H. Forde, and O.D. Mjos The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study Lancet 1 1977 965 968
17. E.J. Niesor, C. Magg, N. Ogawa, H. Okamoto, E. von der Mark, H. Matile, G. Schmid, R.G. Clerc, E. Chaput, D. Blum-Kaelin, W. Huber, R. Thoma, P. Pflieger, M. Kakutani, D. Takahashi, G. Dernick, and C. Maugeais Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport J. Lipid Res. 51 2010 3443 3454
18. E.J. Niesor, E. Chaput, A. Staempfli, D. Blum, M. Derks, and D. Kallend Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects Atherosclerosis 219 2011 761 767
19. V.M. Paromov, and R.E. Morton Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP) J. Biol. Chem. 278 2003 40859 40866 (Pubitemid 37280904)
20. R.S. Rosenson, H.B. Brewer Jr., W.S. Davidson, Z.A. Fayad, V. Fuster, J. Goldstein, M. Hellerstein, X.C. Jiang, M.C. Phillips, D.J. Rader, A.T. Remaley, G.H. Rothblat, A.R. Tall, and L. Yvan-Charvet Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport Circulation 125 2012 1905 1919
21. dal-OUTCOMES Investigators G.G. Schwartz, A.G. Olsson, M. Abt, C.M. Ballantyne, P.J. Barter, J. Brumm, B.R. Chaitman, I.M. Holme, D. Kallend, L.A. Leiter, E. Leitersdorf, J.J. McMurray, H. Mundl, S.J. Nicholls, P.K. Shah, J.C. Tardif, and R.S. Wright Effects of dalcetrapib in patients with a recent acute coronary syndrome N. Engl. J. Med. 367 2012 2089 2099
22. U. Tchoua, W. D'Souza, N. Mukhamedova, D. Blum, E. Niesor, J. Mizrahi, C. Maugeais, and D. Sviridov The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport Cardiovasc. Res. 77 2008 732 739 (Pubitemid 351301865)
23. S.P. Wang, E. Daniels, Y. Chen, J. Castro-Perez, H. Zhou, K.O. Akinsanya, S.F. Previs, T.P. Roddy, and D.G. Johns in vivo effects of anacetrapib on pre-beta HDL: evidence for improvement in HDL remodeling without effects on cholesterol absorption J. Lipid Res. 54 2013 2858 2865